Painkiller headache

Neurology

Volumn 59, Issue 7, 2002, Pages 972-974

  Silberstein, Stephen D ^a   Welch, K M A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; BARBITURIC ACID DERIVATIVE; ERGOT ALKALOID; ERGOTAMINE TARTRATE; OPIATE; SEDATIVE AGENT; TRIPTAN; UNCLASSIFIED DRUG;

CLINICAL FEATURE; DISEASE SEVERITY; DRUG ABUSE; DRUG INDUCED HEADACHE; EDITORIAL; HEADACHE; HUMAN; MIGRAINE; NOCICEPTION; PATHOGENESIS; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; TENSION HEADACHE;

EID: 0037044257     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.59.7.972     Document Type: Editorial

References (17)

1. Silberstein SD, Lipton RB, Goadsby PJ. Headache in clinical practice. Oxford: Isis Medical Media Ltd, 1998.
2. Isler H. Headache drugs provoking chronic headache: historical aspects and common misunderstandings. In: Diener HC, Wilkinson M, eds. Drug-induced headache. Berlin: Springer-Verlag, 1988:87-94.
3. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia, and facial pain. Cephalalgia 1988;8:1-96.
4. Castillo J, Munoz P, Guitera V, Pascual J. Epidemiology of chronic daily headache in the general population. Headache 1999;39:190-196.
5. Wang SJ, Fuh JL, Lu SR, et al. Chronic daily headache in Chinese elderly: prevalence, risk factors and biannual follow-up. Neurology 2000;54:314-319.
6. Micieli G, Manzoni GC, Granella F, Martignoni E, Malferrari G, Nappi G. Clinical and epidemiological observations on drug abuse in headache patients. In: Diener HC, Wilkinson M, eds. Drug-induced headache. Berlin: Springer-Verlag, 1988:20-28.
7. Scher AI, Stewart WF, Lipton RB. Is analgesic use a risk factor for chronic daily headache? Neurology 2001;56:A312. Abstract.
8. Mathew NT, Stubits E, Nigam MR. Transformation of episodic migraine into daily headache: analysis of factors. Headache 1982;22:66-68.
9. Saper JR. Ergotamine dependence. Headache 1987;27:435-438.
10. Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology 1996;47:871-875.
11. Limmroth V, Katsarva Z, Fritsche G, Przywara S, Diener HC. Features of medication overuse headache following overuse of different acute headache drugs. Neurology 2002;59:1011-1014.
12. Welch KM, Nagesh V, Aurora S, Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache 2001;41:629-637.
13. Hagen K, Stovner LJ, Asberg A, Thorstensen K, Bjerve KS, Hveem K. High headache prevalence among women with hematochromatosis: the Nord-Trondelag Health Study. Ann Neurol 2002;51:786-789.
14. Knight YE, Bartsch T, Kaube H, Goadsby PJ. P/Q-type calcium channel blockade in the PAG facilitates trigeminal nociception: a functional genetic link for migraine? J Neurosci 2002;22:RC213.
15. Sternfeld B, Stang P, Sidney S. Relationship of migraine headaches to experience of chest pain and subsequent risk for myocardial infarction. Neurology 1995;45:2135-2142.
16. Gomez-Flores R, Weber RJ. Inhibition of interleukin-2 production and downregulation of IL-2 and transferrin receptors on rat splenic lymphocytes following PAG morphine administration: a role in natural killer and T cell suppression. J Interferon Cytokine Res 1999;19:625-630.
17. Christie MJ, Williams JT, Osborne PB, Bellchambers CE. Where is the locus in opioid withdrawal? Trends Pharmacol Sci 1997;18:134-140.